Selvita plans unit merger. Selvita stock gains 1.37 percent

Published on 10/06/2026 at 15:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales fell 14.00 percent to PLN 158.10 million in the first half of 2026. Selvita stock costs EUR 5.19 after EUR 5.12 on October 6, 2026.

Selvita, PLSLVCR00029, Illustration mit AI erstellt.

Selvita plans to merge its fully controlled subsidiaries Selvita Services and PozLab, while Selvita stock was trading at EUR 5.19 at Lang & Schwarz on October 6, 2026 at 3:39 p.m. CEST, up 1.37 percent versus the prior close of EUR 5.12. The company reported the planned transaction on October 1, 2026, according to Investing.com.

Merger targets lower complexity

Selvita Services is set to absorb PozLab through a transfer of all assets, rights and obligations after registration in Poland's National Court Register. Both subsidiaries are already fully consolidated, so the transaction will not change Selvita's consolidated financial statements.

The stated goal is to simplify the group structure and improve operating synergies in the Drug Development segment. The plan also targets lower costs from running two entities in parallel and a unified commercial brand, according to Investing.com.

First-half sales fell 14.00 percent

The operating backdrop remains demanding. Selvita reported sales of PLN 158.10 million for the first half of 2026, down from PLN 183.76 million in the same period of 2025, while revenue was PLN 164.64 million versus PLN 186.21 million.

Net loss widened to PLN 8.49 million in the first half of 2026 from PLN 5.60 million a year earlier. Adjusted EBITDA excluding the incentive scheme fell to PLN 23.90 million from PLN 30.91 million, according to MarketScreener. The comparison shows that the planned structural simplification arrives alongside weaker group-level earnings, not a change to the consolidated reporting perimeter.

Backlog sets the key test

Selvita's backlog for 2026 stood at PLN 305.70 million as of September 15, 2026, down 8.50 percent year over year. The contrast between divisions is material: Drug Development backlog rose 23.00 percent, while Drug Discovery backlog fell 23.00 percent, according to Quartr.

That split gives the merger a clear operating angle. Management is consolidating entities in the division with stronger recent growth, while the larger Drug Discovery business remains exposed to weaker biotechnology demand and pricing pressure.

Stock gains 1.37 percent

Selvita stock was trading at EUR 5.19 at Lang & Schwarz on October 6, 2026 at 3:39 p.m. CEST, up 1.37 percent versus the prior close of EUR 5.12. On the Warsaw Stock Exchange, SLV.WA was last at PLN 22.70 on October 6, 2026 at 3:34 p.m. CEST, with a market capitalization of PLN 416.6 million and a 52-week range of PLN 20.20 to PLN 49.40.